Integra LifeSciences Reaffirms 2026 Adjusted EPS Guidance
Integra LifeSciences (IART) reaffirmed its adjusted earnings per share guidance for fiscal year 2026, maintaining a range of $2.40 to $2.50. The company also provided Q3 revenue guidance between $410 million and $425 million. In the second quarter, Integra met expectations by delivering on key commitments and achieving strategic milestones across its operations. CEO Stuart Essig expressed optimism about the results, highlighting progress in advancing business priorities. This update reflects continued confidence from management despite broader market uncertainties affecting healthcare stocks.
Tickers: $IART